Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonepcizumab + bevacizumab
- Development stage
- Preclinical
- Lead developer
- Apollo Endosurgery, Inc.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination investigational therapy consisting of **sonepcizumab** and **bevacizumab**, both targeted biologic agents that inhibit angiogenesis via distinct but complementary mechanisms. Sonepcizumab is an antibody directed against sphingosine-1-phosphate (S1P), a bioactive lipid mediator implicated in angiogenesis, vascular permeability, and cancer progression. Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGFA), thereby preventing VEGF-mediated tumor neovascularization. This combined approach aims to more fully suppress angiogenic pathways in cancer (such as renal cell carcinoma), potentially enhancing efficacy compared to VEGF inhibition alone.
- Other names
- sonepcizumab + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)S1P (Site-1 protease)
Beyond the preview
Go deeper on sonepcizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonepcizumab + bevacizumab.